Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJY)
OTHER OTC:UCBJY
UCBJY Stock Chart & Stats
$146.54
$1.86(1.89%)
At close: 4:00 PM EST
$146.54
$1.86(1.89%)
Day’s Range― - ―
52-Week Range$71.39 - $168.70
Previous CloseN/A
Volume2.14K
Average Volume (3M)2.85K
Market Cap
$54.90B
Enterprise Value$48.80B
Total Cash (Recent Filing)$2.47B
Total Debt (Recent Filing)$2.24B
Price to Earnings (P/E)30.2
Beta0.53
Next Earnings
Jul 23, 2026EPS Estimate
2.63Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)3.79
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.33
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda18.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.26
Revenue Forecast (FY)$9.97B
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionRapid adoption of Bimzelx by hidradenitis suppurativa specialists, especially for more severe patients, is driving strong patient retention and underpins ongoing commercial momentum.
Label Expansion And R&D RunwayPlanned label expansions and an active atopic dermatitis development program provide additional commercial runway and could meaningfully increase the addressable patient population.
Management And Leadership ExecutionManagement's focused strategy and recent leadership changes are designed to maximize Bimzelx value in hidradenitis suppurativa and improve execution across the pipeline, supporting clearer long-term earnings drivers.
Bears Say
Expectation SensitivityElevated market expectations make the stock sensitive to downside if Bimzelx adoption or expansion timelines fall short of investor forecasts.
Macroeconomic And Competitive HeadwindsMacroeconomic pressures and competitive overhangs have created a valuation discount that could limit upside until there is clearer evidence of sustained sales growth.
Market Growth Slowdown RiskConcerns that hidradenitis suppurativa market growth may slow after an initial surge could introduce near-term uncertainty around sales trajectory and investor expectations.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $71.39 and its highest was $168.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $54.90B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 23, 2026 which is in 135 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 26, 2026. The company reported $3.785 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.625.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.79 which represents an annual dividend yield of 0.55%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 2.63.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $3.785 in its last earnings report, beating expectations of $3.16. Following the earnings report the stock price went down -7.921%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
15.16%
Trailing 12-Months
Asset Growth
18.72%
Trailing 12-Months
Company Description
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCBJY Company Deck
UCBJY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial story: strong top-line growth, meaningful margin expansion, doubled EPS, sizable commercial traction for BIMZELX and other growth drivers, important regulatory wins (KYGEVVI) and pipeline momentum. Challenges noted include net-price/gross-to-net pressure as access expands, near-term LOE for BRIVIACT, industry headwinds in clinical trials and competitive risks in several programs. On balance the positives (robust growth, profitability, pipeline progress and a strengthened balance sheet) outweigh the challenges, although execution on pricing, trial execution and competitive positioning will be important in 2026.View all UCBJY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---